Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.

Courtney D. DiNardo,Curtis Lachowiez,Koichi Takahashi,Sanam Loghavi,Lianchun Xiao,Tapan M. Kadia,Naval Daver,Maria Adeoti,Nicholas J. Short,Koji Sasaki,Sa Wang,Gautam Borthakur,Ghayas C. Issa,Abhishek Maiti,Yesid Alvarado,Naveen Pemmaraju,Guillermo Montalban Bravo,Lucia Masarova,Musa Yilmaz,Nitin Jain,Michael Andreeff,Elias Jabbour,Guillermo Garcia-Manero,Steven M. Kornblau,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.

2021

PURPOSESixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refra...

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations